Related Experiment Video
Updated: Aug 6, 2026
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Virtual vs. In-Person Training for MinMed™ 780G Initiation: Comparable Effectiveness and Safety in Adults with Type 1
Ana Maria Gómez1,2, Diana Henao-Carrillo1,2, Oscar Muñoz-Velandia2,3
1Endocrinology Unit, Hospital Universitario San Ignacio, Bogotá, Colombia.
Clinical Medicine Insights. Endocrinology and Diabetes
|July 22, 2026
Summary
Virtual and in-person training for the MiniMed™ 780G system are equally effective and safe for adults with type 1 diabetes. Both methods improved time in range and reduced hypoglycemia without significant differences between training modalities.
Area of Science:
- Endocrinology
- Diabetes Technology
Background:
- A knowledge gap exists regarding the comparative effectiveness of virtual versus in-person training for the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system in adults with type 1 diabetes mellitus (T1D).
- Assessing metabolic control and clinical safety is crucial for initiating new diabetes management technologies.
Purpose of the Study:
- To compare the efficacy and safety of virtual versus in-person training for initiating the MiniMed™ 780G AHCL system in adults with T1D.
- To identify factors associated with achieving glycemic targets after system initiation.
Main Methods:
- An observational study comparing retrospective cohorts of adult T1D patients trained in-person versus virtually on the MiniMed™ 780G system.
- Evaluation of metabolic control (Time in Range [TIR]) and safety (hypoglycemia) at 12 weeks post-training.
- Logistic regression analysis to determine factors associated with achieving TIR ≥ 70%.
Main Results:
- No statistically significant differences in TIR (75% virtual vs. 77.5% in-person) or severe hypoglycemia rates were observed between virtual and in-person training cohorts.
- Training modality was not significantly associated with achieving glycemic targets (adjusted OR 0.78).
- Younger age (<45 years) was independently associated with improved metabolic control (adjusted OR 0.08), and higher socioeconomic status showed a trend toward better outcomes (adjusted OR 35.04).
Conclusions:
- Both virtual and in-person training modalities are effective and safe for initiating the MiniMed™ 780G AHCL system in adults with T1D.
- The choice of training modality does not appear to significantly impact metabolic control or safety outcomes at 12 weeks.
- Patient factors such as age and socioeconomic status may play a role in achieving optimal glycemic control with AHCL systems.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...